A Phase III Randomized Placebo-Controlled Study Evaluating Regorafenib Following Completion of Standard Chemotherapy for Patients With Stage III Colon Cancer
Phase of Trial: Phase III
Latest Information Update: 10 Aug 2017
At a glance
- Drugs Regorafenib (Primary)
- Indications Colon cancer
- Focus Therapeutic Use
- Acronyms ARGO
- 03 Jun 2016 Planned End Date changed from 1 Oct 2024 to 1 Jan 2025.
- 03 Jun 2016 Planned primary completion date changed from 1 Aug 2023 to 1 Nov 2023.
- 03 Jun 2016 Status changed from not yet recruiting to recruiting.